1 / 1

Survie sans récidive selon le statut mutationnel de PIK3CA et la prise d’aspirine

Survie sans récidive selon le statut mutationnel de PIK3CA et la prise d’aspirine. PIK3CA sauvage. PIK3CA muté. 100. 100. 80. 80. p = 0,71 Multivariée HR = 0,94 (IC 95 : 0,59-1,49) ; p = 0,786. p = 0,036 Multivariée HR = 0,11 (IC 95 : 0,001-0,83) ; p = 0,027. 60. 60.

jalila
Download Presentation

Survie sans récidive selon le statut mutationnel de PIK3CA et la prise d’aspirine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Survie sans récidive selon le statut mutationnel de PIK3CA et la prise d’aspirine PIK3CA sauvage PIK3CA muté 100 100 80 80 p = 0,71 Multivariée HR = 0,94(IC95 : 0,59-1,49) ; p = 0,786 p = 0,036 Multivariée HR = 0,11(IC95 : 0,001-0,83) ; p = 0,027 60 60 Survie sans récidive (%) Survie sans récidive (%) 40 40 Aspirine Aspirine 20 20 Pas d’aspirine Pas d’aspirine 0 0 0 1 2 3 4 5 0 1 2 3 4 5 Années Années Patients à risque Patients à risque 681 111 649 103 562 90 491 78 409 62 233 33 90 14 82 14 69 13 58 13 47 10 29 6 • ESMO 2013 – D’après Church D et al., abstr. 2161, actualisé • La Lettre du Cancérologue

More Related